Our device launched commercially as world’s first point-and-click skin cancer detection tool

Miami, Florida, November 17, 2020 — DermaSensor Inc., a health technology company designing
tools to better equip primary care providers for skin cancer checks, today announced the launch of their
new point-and-click device in Australia and New Zealand. The company also recently received CE Mark
for use of its product in Europe. The DermaSensor device was designed as an objective tool to support
clinicians’ assessment of suspicious lesions for the most common forms of skin cancer.

After frontline providers identify any lesions of concern for skin cancer on their patients, they
gently touch the small, non-invasive device tip to the lesion. The tool takes instant spectroscopic
recordings, emitting light and capturing the wavelengths of light that scatter off cellular structures
beneath the skin’s surface and then back to the spectral sensor. A proprietary algorithm analyzes the light and provides an immediate “Higher Risk” or “Lower Risk” result.

“Globally there are around 8 million new skin cancer cases each year, and about two-thirds of
skin issues are first evaluated by non-specialists,” states DermaSensor’s CEO, Cody Simmons. “If the
world’s millions of primary care providers were equipped with an easy-to-use, low-cost tool that helped
them better assess skin cancer, we believe that tens of thousands of lives could be saved each year
since nearly all skin cancer is curable if detected early. That is why our company has spent the last
decade conducting several clinical studies and engineering our current miniaturized one-pound, handheld
device from what used to be a 30-pound, microwave-size spectroscopy system.”

In addition to their commercial launch, DermaSensor is also announcing today the results of a
U.S. study that show the clinical utility potential of the DermaSensor device. In a randomized,
prospective study with 57 primary care physicians, these physicians made over 5,000 assessments of
skin lesions. The study results showed that physicians’ correctly referred or biopsied cancerous lesions
13 percent more when the DermaSensor output was available to them, compared to their evaluations
with no device output. The physicians’ cancer sensitivity increased from 81% to 94%, and this
improvement was statistically significant (p <.0001).

“Approximately two-thirds of Australians are diagnosed with skin cancer, so it’s been recognized as a
major public health issue in Australia for decades,” says DermaSensor’s Kevin Scrimshaw, Commercial
Director for Australia and New Zealand. “Despite that, there are still thousands of deaths from skin
cancer every year here, and a great portion of those could have been prevented if those skin cancers
were caught early. DermaSensor is launching to support Australia’s GPs in the fight against skin cancer
by assisting them in identifying skin cancers. The earlier, the better.”

The DermaSensor device is currently CE Marked and is registered and available for sale in Australia and
New Zealand. In the United States, the device is currently investigational and not yet available for sale.
To learn more about the device and how to purchase, please visit www.ds-usa-a.dsadmin.dermasensor.com.

About DermaSensor Inc.:

DermaSensor Inc. is a health technology company designing non-invasive tools to better equip primary care
providers for skin cancer checks. The DermaSensor device is an affordable, handheld tool that uses machine
learning and spectroscopy to evaluate skin lesions for potential cancer in a matter of seconds. DermaSensor’s
mission is to improve outcomes and save on healthcare costs by providing broad access to effective skin
cancer checks since the large majority of Americans do not receive an annual skin check.

Forward-Looking Statements:

This press release includes forward-looking statements. The expectations, estimates, and projections of
DermaSensor Inc. may differ from its actual results and you should not rely on these forward-looking
statements as predictions of future events. DermaSensor does not undertake or accept any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any
change in its expectations or any change in events, conditions, or circumstances on which any such
statement is based.